Kriya Therapeutics’ $150M Boost to Series C Funding for Breakthrough Gene Therapies

Kriya Therapeutics, a biopharmaceutical company focused on gene therapy, has secured $150 million for its Series C funding round. This significant funding injection further propels the company’s mission to advance cutting-edge gene therapies and propel its drug development endeavors to new heights.

Having already secured a total of over $430 million in Series C funding, Kriya Therapeutics has now amassed an impressive $600 million since its inception in 2019. With a stronghold in California, the company has been consistently attracting substantial investments, with Patient Square Capital leading a $270 million Series C financing round in May 2022, following $80 million in Series A funding in May 2020 and $100 million in Series B.

Kriya Therapeutics has set its sights on groundbreaking advancements, planning to progress its undisclosed gene therapies into clinical trials. Alongside this, the company is dedicated to further enhancing its computational, engineering, and manufacturing platforms, ensuring that its therapies reach their full potential.

CEO Shankar Ramaswamy emphasized the company’s commitment to efficient gene therapy development, stating, “Our investments in world-class infrastructure and talent have supported our ability to move with unprecedented efficiency in the engineering and production of gene therapies.” With a passion for transformative healthcare, Kriya Therapeutics aims to provide better treatment options for patients battling metabolic, neurological, and ophthalmological conditions.

The company’s diverse pipeline encompasses therapies for metabolic disorders like diabetes and glycogen storage diseases, neurological diseases including epilepsy, and ophthalmological conditions like diabetic retinopathy. The acquisition of Redpin Therapeutics has further strengthened Kriya’s neurological gene therapy portfolio.

Though specifics about its treatments are yet to be revealed, Kriya Therapeutics made a splash at the 2023 American Society of Gene and Cell Therapy Annual Meeting. The company presented ten abstracts detailing its groundbreaking technology and manufacturing platforms, hinting at the transformative potential of its gene therapies.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts